Phosphatidylinositol-3-Kinase Inhibition in Follicular Lymphoma
We describe the efficacy and toxicities of phosphatidylinositol-3-kinase inhibitors. Response rates in highly refractory disease are high, demonstrate few long-term remissions, and have high long-term toxicity. Early data on dosing and combination strategies are promising and may change how we use these agents in the coming years.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Ryan C. Lynch, Ajay K. Gopal Source Type: research